Entrectinib

• FINPROVE - The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs Recruiting
  2024-517478-68-01 Phase II 1 country HUS-Yhtymae
• A Rollover Study for Patients Previously Enrolled in a Genentech and/or F.Hoffman-La Roche Sponsored Study Recruiting
  2023-504263-16-00 Phase III 4 countries F. Hoffmann-La Roche AG
• Improving public cancer care by implementing precision medicine in Norway Recruiting
  2023-507894-16-00 Phase II 1 country Oslo University Hospital HF
• DRUP trial Recruiting
  2023-509152-33-00 Phase II 1 country Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
• A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lun… Ended
  2023-507494-18-00 Phase III 10 countries F. Hoffmann-La Roche AG
• Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study Ended
  2023-507418-28-00 Phase II 8 countries F. Hoffmann-La Roche AG
• Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have … Ended
  2023-505088-35-00 Phase I/II 4 countries F. Hoffmann-La Roche AG
• Study of Tumor Alterations Responsive to Targeting Receptor Kinases-2 Ended
  2023-505034-10-00 Phase II 6 countries F. Hoffmann-La Roche AG

Showing 1–8 of 8 trials